Innovation Strategy & M&A
Innovation Strategy & M&A
De-risk build-buy-partner moves with data-driven assessment of R&D and commercial opportunity and fit analyses.
Reimbursement & Market Access
Reimbursement & Market Access
Identify needed codes, evidence to secure coverage, and payment levers early—accelerating clinical adoption and payer acceptance.
Market & Customer Insights
Market & Customer Insights
Voice-of-stakeholder research pinpoints unmet needs and adoption drivers across clinicians, payers, purchasers, and patients.
HEOR Consulting
HEOR Consulting
Health-economic models quantify budget impact or cost-effectiveness—arming you with value dossiers that win formulary decisions.
Integrated Evidence Planning
Integrated Evidence Planning
Seamlessly align clinical, economic, and real-world data generation to demonstrate value and accelerate regulatory approval, clinical adoption and payer coverage.
The WISeR Model: CMS's Prior Authorization Demonstration Could Dramatically Reshape Medicare Reimbursement Strategies for Medical Device Manufacturers and
The Centers for Medicaid and Medicare Services (CMS) proposed Wasteful and Inappropriate Service Reduction (WISeR) Model, running from January 1, 2026, to December 31,2031, in six states¹, represents a major shift in how Medicare approaches utilization management for Fee-for-Service beneficiaries (traditional Medicare). While initially limited in scope, broader adoption of the program would impact manufacturers and beneficiaries. WISeR warrants attention for manufacturers who have built commercial access, adoption and reimbursement strategies around Medicare's traditional approaches towards coverage and claims processing.
Our Tim Sheflin has the insights.
Strategic Expansion into Market Adjacencies: Unlocking Growth Opportunities in MedTech and HealthTech
Identifying the right adjacent market is an inherently complex endeavor. It demands a disciplined, systematic approach that begins with a cross-functional evaluation of a company’s strategic priorities, growth drivers, and risk tolerance, while also considering the potential for technological and operational synergies. Close adjacencies (defined as being in the immediate proximity of a company’s core business) often provide faster, lower-risk paths to expansion, but more distant adjacencies may represent substantially larger, longer-term market opportunities.
Cinzia Metallo explains.
Build, Buy or Partner? How to Balance Risk and Opportunity for Strategic MedTech Growth
Navigating the build/buy/partner dilemma requires a clear understanding of a company’s strategic priorities, stage of development, long-term growth objectives, resources, and risk tolerance. Full-scale acquisition may be appropriate for a large MedTech company with a global footprint and strong integration capabilities. A phased approach may be better suited to smaller companies with more limited access to capital. Such an approach could begin with a partnership during early product development and progress to an equity investment or full acquisition as confidence in the solution’s value increases (e.g., through clinical validation or reimbursement alignment) or as market conditions become more favorable.
While the optimal path is inherently company and technology-specific, several key questions and core action items consistently underpin effective build/buy/partner decision-making.
